- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | RA Capital's biotech incubator lays off staffers: Stat | ||
| Mi | ADC Therapeutics drops only clinical-stage drug after reviewing phase 1 leukemia data | ||
| Mi | Allogene lays off 28% of staff to extend runway amid delays to CAR-T updates | ||
| Mi | Alumis' Acelyrin merger back on track after shareholders unswayed by activist investor | ||
| Mi | Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs | ||
| Mi | Kyverna lays off 16% of staff as autoimmune CAR-T plans pick up pace | ||
| Mi | GSK pays $1.2B upfront for Boston Pharmaceuticals' lead liver disease drug | ||
| Di | Arcturus stops work on early-stage vaccine programs in effort to 'streamline resources' | ||
| Di | Erasca enters another era, seeks partner for ph. 3 ex-Novartis asset | ||
| Di | Atara lays off more staff this year despite FDA lifting clinical hold | ||
| Di | GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs | ||
| Di | Leap halves head count, narrows lead cancer drug's focus amid 'difficult market environment' | ||
| Di | Appeals court reignites CRISPR discovery row, raising questions about gene-editing biotech patents | ||
| Di | Dutch biotech Azafaros gains €132M series B to fund phase 3 trials of brain-penetrant drug | ||
| Di | Galapagos gets cold feet over plans to split up company | ||
| Mo | Former Inhibikase leader launches new biotech for midstage Parkinson's asset | ||
| Mo | Tango dances away from preclinical work to extend cash runway, while Avalo lays out spending options | ||
| Mo | Lexeo laid off 15% of staff in April to focus on lead cardiac gene therapies | ||
| Mo | Dynavax's feud with activist investor heats up ahead of annual meeting | ||
| Fr | Vir's 'functional cure' candidate for hepatitis B misses mark in phase 2 | ||
| Fr | Leo tames eczema in phase 2b, reporting primary endpoint hit for ex-argenx asset | ||
| Fr | Qilu Pharmaceutical pays $38M upfront for greater China rights to Minghui's ADC | ||
| Fr | Sanofi axes IGM pact, sparking 80% layoffs and facility closures | ||
| Fr | NIH terminated $1.8B in grants in 40 days under Trump administration: study | ||
| 08.05. | Vor Bio to wind down, halting cell therapy trials and shedding most staff |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .